

CV Date	19/12/2025
---------	------------

Part A. PERSONAL INFORMATION

First Name	Alicia		
Family Name	Rodríguez Gascón		
Sex		Date of Birth	
ID number Social Security, Passport			
URL Web			
Email Address			
Open Researcher and Contributor ID (ORCID)			

A.1. Current position

Job Title	Catedrático de Universidad		
Starting date	2021		
Institution	Universidad del País Vasco UPV/EHU		
Department / Centre	Farmacia y Ciencias de los Alimentos / Facultad de Farmacia		
Country		Phone Number	
Keywords	Drugs evaluation; Pharmaceutic industry; Biomedicine		

A.3. Education

Degree/Master/PhD	University / Country	Year
Pharmacy	University of Salamanca	1992
Degree in Pharmacy	University of Salamanca	1988

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 Scientific paper.** Julen Rodriguez-Castejon; Paula Fernandez-Muro; Marina Beraza-Millor; Maria Angeles Solinis; Alicia Rodriguez-Gascon; Ana del Pozo-Rodriguez. 2025. Asialofetuin-Coupled Lipid-Based nanosystems to target the Asialoglycoprotein receptor: Delivering genes to hepatocytes for the treatment of Fabry disease. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. ELSEVIER. 210. ISSN 0928-0987. WOS (1) <https://doi.org/10.1016/j.ejps.2025.107118>
- 2 Scientific paper.** 2024. Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital. European Journal of Clinical Microbiology & Infectious Diseases.
- 3 Scientific paper.** Julen Rodriguez-Castejon; Josee A. Plantinga; Marina Beraza-Millor; Maria Angeles Solinis; Alicia Rodriguez-Gascon; Ana del Pozo-Rodriguez; Jan A. A. M. Kamps. 2024. Gene therapy with lipid nanoparticles for Fabry disease: Leveraging E-selectin for targeted delivery to endothelial cells. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY. ELSEVIER. 99. ISSN 1773-2247. WOS (0) <https://doi.org/10.1016/j.jddst.2024.105954>
- 4 Scientific paper.** Helena Barrasa; Miguel Angel Moran; Leire Fernandez-Ciriza; Arantxa Isla; Maria angeles Solinis; Andres Canut-Blasco; Alicia Rodriguez-Gascon. 2024. Optimizing Antibiotic Therapy for *Stenotrophomonas maltophilia* Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach. ANTIBIOTICS-BASEL. MDPI. 13. ISSN 2079-6382. WOS (1) <https://doi.org/10.3390/antibiotics13060553>

- 5 **Scientific paper.** Maria Ubals; Patricia Nadal-Baron; Mainer Arando; et al; Oriol Mitja. 2024. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial. LANCET INFECTIOUS DISEASES. ELSEVIER SCI LTD. 24, pp.404-416. ISSN 1473-3099. WOS (4) [https://doi.org/10.1016/S1473-3099\(23\)00683-7](https://doi.org/10.1016/S1473-3099(23)00683-7)
- 6 **Scientific paper.** Arantxa Isla; Ana Alarcia-Lacalle; Maria Angeles Solinis; Ana del Pozo-Rodriguez; Zurine Abajo; Maria Cabero; Andres Canut-Blasco; Alicia Rodriguez-Gascon. 2024. Population pharmacokinetics of oral fosfomycin calcium in healthy women. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. OXFORD UNIV PRESS. 79, pp.2837-2845. ISSN 0305-7453. WOS (0) <https://doi.org/10.1093/jac/dkae295>
- 7 **Scientific paper.** Julen Rodriguez-Castejon; Marina Beraza-Millor; Maria angeles Solinis; Alicia Rodriguez-Gascon; Ana del Pozo-Rodriguez. 2024. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review. DRUG DELIVERY AND TRANSLATIONAL RESEARCH. SPRINGER HEIDELBERG. 14, pp.2615-2628. ISSN 2190-393X. WOS (2) <https://doi.org/10.1007/s13346-024-01583-0>
- 8 Ana Alarcia-Lacalle; Andres Canut-Blasco; Maria Angeles Solinis; Arantxa Isla; Alicia Rodriguez-Gascon. 2025. Clinical efficacy, safety and pharmacokinetics of novel β -lactam/ β -lactamase inhibitor combinations: a systematic review. JAC-ANTIMICROBIAL RESISTANCE. OXFORD UNIV PRESS. 7. WOS (1) <https://doi.org/10.1093/jacamr/dlaf096>
- 9 Ubals M; Nadal-Baron P; Arando M; et al; Mitjà O. 2024. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial. The Lancet. Infectious diseases. ISSN 1473-3099. [https://doi.org/10.1016/S1473-3099\(23\)00683-7](https://doi.org/10.1016/S1473-3099(23)00683-7)
- 10 Marina Beraza-Millor; Julen Rodriguez-Castejon; Ana del Pozo-Rodriguez; Alicia Rodriguez-Gascon; Maria Angeles Solinis. 2024. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems. BIODRUGS. ADIS INT LTD. ISSN 1173-8804. WOS (1) <https://doi.org/10.1007/s40259-024-00674-1>

C.3. Research projects and contracts

- 1 **Project.** Grupo Consolidado del Sistema Universitario Vasco. 01/01/2022-31/12/2025. 96.000 €.
- 2 **Project.** MEDICAMENTOS 3D FARMA - Preparación y caracterización de medicamentos mediante dosificación automática e impresión 3D: aplicación en medicina personalizada para farmacia hospitalaria. 2023333051. Gobierno Vasco. Proyectos de investigación en Salud. Alicia Rodríguez Gascón. 01/01/2023-31/12/2024. 55.178 €.
- 3 **Project.** Nuevos medicamentos basados en ácidos nucleicos para tratar las distrofias de retina asociadas a mutaciones en PDEA, PDEB, AIPL y IMPDH1. (Universitat de Barcelona/Universidad del País Vasco). 01/12/2022-01/12/2024. 50.000 €. Principal investigador.
- 4 **Project.** Aplicación de nano-compuestos como sistemas de entrega no viral para el desarrollo de terapia CAR-T. (Universidad del País Vasco). 01/01/2022-31/12/2022. 21.175 €.
- 5 **Project.** Aplicación de nano-compuestos como sistemas de entrega no viral para el desarrollo de terapia CAR-T. Gobierno Vasco. Proyectos de investigación en Salud. Marian Solinís Aspiazú. From 01/01/2022. 21.175 €.

C.4. Activities of technology / knowledge transfer and results exploitation

- 1 MA Solinis; A del Pozo-Rodriguez; A Rodríguez-Gascón; I Gómez Aguado; M Vicente Pascual. EP19383183.1. Golden lipid nanoparticles for gene therapy Spain. 23/12/2019. Universidad del País Vasco.
- 2 AR Gascón; MA Solinis; A del Pozo Rodríguez; D Delgado; JL Pedraz. P200901664. Lipid nanoparticles for gene therapy EP2460516B1, US9675710B2 Spain. 13/07/2017. Universidad del País Vasco UPV/EHU.

3 AR Gascón; MA Solinís; A del Pozo Rodríguez; D Delgado; E Fernández. 201031897. Lipid nanoparticles for the treatment of ocular diseases EP19383183.1 Spain. 26/04/1013. UPV/EHU y Universidad Miguel Hernández de Elche.